Celiac disease
Program: IgY-112 Stage: Discovery IgY for Celiac disease contain polyclonal IgY antibodies that block the interaction of hypersensitive or excessive mucosal immune responses with microbial and protein components that are associated with celiac disease pathogenesis. We are researching the effectiveness of an oral therapeutic using a capsule-based format to deliver the antibodies directly [...]